GSK to Pay $750 Million Fine for Tainted Drugs

Oct. 26, 2010
Pleaded guilty to manufacturing and distributing adulterated drugs made at a now-closed Puerto Rico facility

British pharmaceutical giant GlaxoSmithKline has agreed to plead guilty in a tainted drug scandal and to pay a $750-million fine, the Justice Department said on Oct. 26.

Pharmco Puerto Rico, a subsidiary of GlaxoSmithKline admitted it was guilty of the charges relating to the manufacture and distribution of certain adulterated drugs made at a now-closed Puerto Rico facility, the department said.

The resolution includes a criminal fine of $150 million and a civil settlement of $600 million to the federal government and states.

Four drugs manufactured by Pharmco were deemed adulterated after they did not conform to U.S. safety requirements and did not have the "quality and purity characteristics which it purported or was represented to possess."

The drugs, manufactured at the plant between 2001 and 2005, are Kytril, Bactroban, Paxil CR and Avandamet.

The guilty plea and sentence is not final until accepted by the U.S. District Court in Boston, Massachusetts, the department said.

Copyright Agence France-Presse, 2010

Popular Sponsored Recommendations

Digitally Transforming Data and Processes With Product Lifecycle Management

Oct. 29, 2023
Manufacturers face increasing challenges in product development as they strive to consistently deliver improved results. Discover how industry leaders are improving time-to-market...

Legacy Phone Lines Are Draining Your Profits

Oct. 30, 2023
Copper wire phone line expenses that support emergency devices could be costing your company millions of dollars in wasteful overhead expenses. Rates have been skyrocketing while...

Beware Extreme Software

Sept. 24, 2023
As a manufacturer, you understand the importance of staying ahead of the curve and being proactive in your approach to technology. With the rapid pace of change in the industry...

Why DataOps may be the key to unlocking the full potential of digital transformation

Nov. 3, 2023
Read the 2023 market survey conducted by IndustryWeek

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!